Companies › TELO

Telomir Pharmaceuticals Inc (TELO)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001971532 · EDGAR filings · Updated 2026-07-28

Telomir Pharmaceuticals Inc (TELO) has reported institutional ownership of 6.5%, with 27 institutional managers holding positions valued at $2.91M per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings.

Filings this week (4)

• 2026-07-28 — Proxy statement (DEF 14A) filed
• 2026-07-27 — Insider transaction reported (Form 4)
• 2026-07-27 — Insider transaction reported (Form 4)
• 2026-07-27 — Insider transaction reported (Form 4)

Every filing links to the official SEC document. Real-time filing alerts for this company are available inside the app.

Latest updates

• 2026-06-15 — Current report (8-K) filed
• 2026-06-09 — Initial insider ownership filed (Form 3)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, Telomir Pharmaceuticals Inc has 27 institutional holders and institutional ownership of 6.5%.

Insider activity

Insiders reported 0 transactions (0 buys, 0 sells) across 1 reporting insiders, with a net reported value of $0.

Data flags from SEC filings

Related companies

GREENLAND MINES LTD (GRML) · PDS BIOTECHNOLOGY CORP (PDSB) · IRIDEX CORP (IRIX) · Celularity Inc (CELU) · Lantern Pharma Inc (LTRN) · SERINA THERAPEUTICS INC (SER)